泰利索图祖马布Vedotin:第一个批准
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|July 30, 2025
概括
泰利索图祖马布维多丁是一种新的抗体-药物结合物,已批准用于高c-MET过度表达的非小细胞肺癌 (NSCLC). 这种向治疗为以前用全身疗法治疗的患者提供了新的治疗选择.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 这种c-mesenchymal-epithelial转变因子 (c-MET) 蛋白与各种固体瘤有关.
- 过度表达c-MET是某些癌症的已知驱动因素,包括非小细胞肺癌 (NSCLC).
- 针对性治疗对于改善晚期NSCLC的结果至关重要.
研究的目的:
- 为了总结telisotuzumab vedotin的发展里程碑.
- 为了突出这一新型抗体-药物结合物的监管批准过程.
- 为了在NSCLC中提供加速批准的背景.
主要方法:
- 开发一种针对c-MET的抗体-药物联合体 (ADC).
- 临床试验评估在固体瘤中的疗效和安全性.
- 监管提交和审查流程用于加速批准.
主要成果:
- 泰利索图祖马布维多丁 (EMRELISTM) 向的是c-MET蛋白.
- 美国于2025年5月14日授予加速批准.
- 适用于先前全身治疗后高c-MET过度表达的局部晚期或转移性非状NSCLC的成年患者.
结论:
- 泰利索图祖马布维多丁 (Telisotuzumab vedotin) 代表了针对NSCLC的向治疗的重大进展.
- 批准意味着针对特定患者群体的新疗法选择.
- 针对固体瘤的进一步研究和开发正在进行中.
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
225
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
225
Tumor Immunotherapy
662
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
662


